keyword
MENU ▼
Read by QxMD icon Read
search

Deauville lymphoma

keyword
https://www.readbyqxmd.com/read/28264597/report-of-the-6th-international-workshop-on-pet-in-lymphoma
#1
Cristina Nanni, Anne Ségolène Cottereau, Egesta Lopci, Caroline Bodet-Milin, Monica Coronado, Barbara Pro, Wong Seog Kim, Judith Trotman, Sally Barrington, Ulrich Duhrsen, Thierry Vander Borght, Elena Zamagni, Françoise Kraeber-Bodéré, Christina Messiou, Alain Rahmouni, Irène Buvat, Marc Andre, Mark Hertzberg, Wim Oyen, Olivier Casasnovas, Stefano Luminari, Laurent Garderet, Françoise Montravers, Carsten Kobe, Regine Kluge, Annibale Versari, Emanuele Zucca, Philippe Moreau, Bruce Cheson, Corinne Haioun, Andrea Gallamini, Michel Meignan
Two hundred and ten nuclear medicine physicians, radiologists, and hematologists from 26 countries attended the 6th International Workshop on Positron Emission Tomography (PET) in Lymphoma and Myeloma held in Menton, France, in September 2016. The meeting was under the auspices of the European Lymphoma Institute (ELI), the European Association of Nuclear Medicine (EANM) the Lymphoma Study Association (LYSA), the Italian Foundation on Lymphoma (FIL) and the Carnot Institute for Lymphoma (CALYM). Forty scientific posters were presented...
March 7, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28236583/progression-free-survival-of-early-interim-pet-positive-patients-with-advanced-stage-hodgkin-s-lymphoma-treated-with-beacoppescalated-alone-or-in-combination-with-rituximab-hd18-an-open-label-international-randomised-phase-3-study-by-the-german-hodgkin-study
#2
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, Ulrich Mey, Stefanie Kreissl, Richard Greil, Jana Markova, Michaela Feuring-Buske, Julia Meissner, Ulrich Dührsen, Helmut Ostermann, Ulrich Keller, Georg Maschmeyer, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Hans Eich, Christian Baues, Harald Stein, Michael Fuchs, Volker Diehl, Andreas Engert
BACKGROUND: Advanced stage Hodgkin's lymphoma represents a heterogeneous group of patients with different risk profiles. Data suggests that interim PET assessment during chemotherapy is superior to baseline international prognostic scoring in terms of predicting long-term treatment outcome in patients with Hodgkin's lymphoma. We therefore hypothesised that early interim PET-imaging after two courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) might be suitable for guiding treatment in patients with advanced stage Hodgkin's lymphoma...
February 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28151888/pediatric-hodgkin-lymphoma-predictive-value-of-interim-18f-fdg-pet-ct-in-therapy-response-assessment
#3
Cristina Ferrari, Artor Niccoli Asabella, Nunzio Merenda, Corinna Altini, Margherita Fanelli, Paola Muggeo, Francesco De Leonardis, Teresa Perillo, Nicola Santoro, Giuseppe Rubini
We investigated the prognostic value of interim F-FDG PET/CT (PET-2) in pediatric Hodgkin lymphoma (pHL), evaluating both visual and semiquantitative analysis.Thirty pHL patients (age ≤16) underwent serial F-FDG PET/CT: at baseline (PET-0), after 2 cycles of chemotherapy (PET-2) and at the end of first-line chemotherapy (PET-T). PET response assessment was carried out visually according to the Deauville Score (DS), as well as semiquantitatively by using the semiquantitative parameters reduction from PET-0 to PET-2 (ΔΣSUVmax0-2, ΔΣSUVmean0-2)...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28143954/early-treatment-intensification-with-r-ice-and-90y-ibritumomab-tiuxetan-zevalin-beam-stem-cell-transplantation-in-patients-with-high-risk-diffuse-large-b-cell-lymphoma-patients-and-positive-interim-pet-after-4-cycles-of-r-chop-14
#4
Mark Hertzberg, Maher K Gandhi, Judith Trotman, Belinda Butcher, John Taper, Amanda Johnston, Devinder Gill, Shir-Jing Ho, Gavin Cull, Keith Fay, Geoff Chong, Andrew Grigg, Ian D Lewis, Sam Milliken, William Renwick, Uwe Hahn, Robin Filshie, George Kannourakis, Anne-Marie Watson, Pauline Warburton, Andrew Wirth, John F Seymour, Michael S Hofman, Rodney J Hicks
In the treatment of diffuse large B-cell lymphoma, a persistently positive [(18)F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whether treatment intensification with R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) chemotherapy followed by 90Y-ibritumomab tiuxetan-BEAM (BCNU, etoposide, cytarabine, and melphalan) for high-risk diffuse large B-cell lymphoma patients who are positive on interim PET scan after 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, and prednisone) can improve 2-year progression-free survival from a historically unfavorable rate of 40% to a rate of 65%...
February 2017: Haematologica
https://www.readbyqxmd.com/read/28132716/-18-f-fdg-pet-mri-in-lymphoma-patients
#5
Eva Ferdová, Jiří Ferda, Jan Baxa
The introduction of hybrid PET/MRI imaging using integrated systems into clinical practice has opened up the possibility of reducing the radiation dose from hybrid imaging by eliminating the contribution from computed tomography. Studies comparing the possibilities of PET/CT and PET/MRI imaging demonstrated it is possible to use the advantages of the high contrast resolution of magnetic resonance for soft tissue and bone marrow along with PET records in a quality comparable to PET/CT imaging. The significant feature for PET imaging in Hodgkińs lymphoma is that it is a tissue with high levels of radiopharmaceutical accumulation, which decreases proportionally after successful therapeutic effect, the effect of therapy is assessed using Deauville score system on interim examinations...
January 23, 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28068241/chemotherapy-response-assessment-by-fdg-pet-ct-in-early-stage-classical-hodgkin-lymphoma-moving-beyond-the-five-point-deauville-score
#6
Sarah A Milgrom, Wenli Dong, Mani Akhtari, Grace L Smith, Chelsea C Pinnix, Osama Mawlawi, Eric Rohren, Naveen Garg, Hubert Chuang, Zeinab Abou Yehia, Jay P Reddy, Jillian R Gunther, Joseph D Khoury, Tina Suki, Eleanor M Osborne, Yasuhiro Oki, Michelle Fanale, Bouthaina S Dabaja
PURPOSE: In early-stage classical Hodgkin lymphoma, fluorodeoxyglucose positron emission tomography (PET)-computed tomography (CT) scans are performed routinely after chemotherapy, and the 5-point Deauville score is used to report the disease response. We hypothesized that other PET-CT parameters, considered in combination with Deauville score, would improve risk stratification. METHODS AND MATERIALS: Patients treated for stage I to II Hodgkin lymphoma from 2003 to 2013, who were aged ≥18 years and had analyzable PET-CT scans performed before and after chemotherapy, were eligible...
February 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27932560/reply-neither-post-treatment-pet-ct-nor-interim-pet-ct-using-deauville-criteria-predicts-outcome-in-pediatric-hodgkin-lymphoma
#7
Sainath Bhethanabhotla, Sameer Bakhshi
No abstract text is available yet for this article.
December 8, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27901328/prognostic-value-of-interim-fdg-pet-ct-in-patients-older-than-60-years-with-diffuse-large-b-cell-lymphoma-treated-by-pmitcebo-plus-rituximab-comparison-between-deauville-5-point-scale-and-international-harmonization-project-criteria
#8
Naelle Lombion, Philippe Robin, Adrian Tempescul, Pierre Y LE Roux, Ulrike Schick, Gaëlle Guillerm, Jean C Ianotto, Christian Berthou, Pierre Y Salaün, Ronan Abgral
BACKGROUND: Advanced age is an independent poor prognostic factor of diffuse large B-cell lymphoma. PMitCEBO is an alternative to CHOP to decrease side effects in elderly patients. Many studies have shown prognostic value of an interim FDG PET-CT to predict survival. A recent consensus (ICML, Lugano 2013) has suggested using the 5-point scale Deauville criteria instead of those of the international harmonization project (IHP) to visually assess the response on interim PET. The objective of this study was to evaluate the prognostic value of an interim FDG PET-CT in patients older than 60 with treated DLBCL and to compare IHP and 5-PS Deauville visual interpretation to predict survival...
November 30, 2016: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27754902/post-treatment-pet-ct-rather-than-interim-pet-ct-using-deauville-criteria-predicts-outcome-in-pediatric-hodgkin-lymphoma-a-prospective-study-comparing-pet-ct-versus-conventional-imaging
#9
Sameer Bakhshi, Sainath Bhethanabhotla, Rakesh Kumar, Krishankant Agarwal, Punit Sharma, Sanjay Thulkar, Arun Malhotra, Deepa Dhawan, Sreenivas Vishnubhatla
BACKGROUND: Data about significance of (18)F-FDG positron emission tomography (PET) at interim assessment and end of treatment in pediatric Hodgkin lymphoma (HL) are limited. METHODS: Patients (≤18 years) with HL were prospectively evaluated with contrast-enhanced computed tomography (CECT) and PET combined with low-dose CT(PET-CT) at baseline, post 2 cycles of chemotherapy and post completion of treatment. Revised international working group criteria (RIW) and Deauville (DA) five point-scale for response assessment by PET-CT were used...
October 6, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27718766/value-of-interim-fdg-pet-ct-for-predicting-outcome-of-patients-with-angioimmunoblastic-t-cell-lymphoma
#10
Seung Hwan Moon, Ah Young Lee, Won-Seog Kim, Seok Jin Kim, Young Seok Cho, Yearn Seong Choe, Byung-Tae Kim, Kyung-Han Lee
Subjects were 45 patients with angioimmunoblastic T-cell lymphoma (AITL) who underwent 2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) at baseline and interim after 2-4 cycles. Predictors of progression-free survival (PFS) and overall survival (OS) were assessed. Positive interim PET/CT (Deauville score ≥3) was a significant independent predictor of poor PFS (Hazard ratio, 4.42; p=.028), and showed marginal significance to predict OS (p=.065). Less than 60% decrease in the average change of maximum standardized uptake value normalized by lean body mass (SULmax) also was a significant independent predictor of poor PFS (Hazard ratio, 12...
October 9, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27688726/primary-mediastinal-b-cell-lymphoma-metabolic-and-anatomical-features-in-18fdg-pet-ct-and-response-to-therapy
#11
Anna Kocurek, Bogdan Małkowski, Agnieszka Giza, Wojciech Jurczak
AIM OF THE STUDY: Determining the role of PET/CT imaging in the evaluation of treatment efficacy in primary mediastinal B-cell lymphoma (PMBCL). MATERIAL AND METHODS: Retrospective analysis of seven PMBCL patients, treated at the University Hospital in Krakow, with interim PET/CT after the third course of chemo-immunotherapy.The analysis was based on the calculation of exact tumour volume and metabolic activity, compared with initial values (directly after diagnosis)...
2016: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/27684851/fdg-pet-ct-response-in-diffuse-large-b-cell-lymphoma-reader-variability-and-association-with-clinical-outcome
#12
Eun Ji Han, Joo Hyun O, Hyukjin Yoon, Seung Eun Jung, Gyeongsin Park, Byung Ock Choi, Seok-Goo Cho
F-18-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is essential for monitoring response to treatment in patients with diffuse large B-cell lymphoma (DLBCL) and qualitative interpretation is commonly applied in clinical practice. We aimed to evaluate the interobserver agreements of qualitative PET/CT response in patients with DLBCL and the predictive value of PET/CT results for clinical outcome.PET/CT images were obtained for patients with DLBCL 3 times: at baseline, after 3 cycles of first-line chemotherapy (interim), and after completion of chemotherapy...
September 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27675922/postchemotherapy-positron-emission-tomography-computed-tomography-scans-in-early-stage-hodgkin-lymphoma-moving-beyond-the-deauville-5-point-scale
#13
S A Milgrom, W Dong, M Akhtari, G L Smith, C C Pinnix, O R Mawlawi, E M Rohren, N Garg, H H Chuang, Z Abou Yehia, J Reddy, J R Gunther, E M Osborne, Y Oki, M Fanale, B Dabaja
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27545416/training-improves-the-interobserver-agreement-of-the-expert-positron-emission-tomography-review-panel-in-primary-mediastinal-b-cell-lymphoma-interim-analysis-in-the-ongoing-international-extranodal-lymphoma-study-group-37-study
#14
Luca Ceriani, Sally Barrington, Alberto Biggi, Bogdan Malkowski, Ur Metser, Annibale Versari, Maurizio Martelli, Andrew Davies, Peter W Johnson, Emanuele Zucca, Stéphane Chauvie
The International Extranodal Lymphoma Study Group (IELSG)-37 is a prospective randomized trial assessing the role of consolidation mediastinal radiotherapy after immunochemotherapy to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMBCL). It is a positron emission tomography (PET) response-guided study where patients obtaining a complete metabolic response on an end-of-therapy PET-computed tomography (CT) scan evaluated by a central review are randomized to receive radiotherapy or no further treatment...
August 22, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27469362/18f-fdg-pet-for-measurement-of-response-and-prediction-of-outcome-to-relapsed-or-refractory-mantle-cell-lymphoma-therapy-with-bendamustine-rituximab
#15
Dominick Lamonica, Daniel A Graf, Mihaela C Munteanu, Myron S Czuczman
In a single-arm, phase 2 clinical trial, bendamustine-rituximab (BR) demonstrated an overall response rate of 82% among 45 patients with relapsed or refractory mantle cell lymphoma (MCL), with manageable tolerability. A prespecified (18)F-FDG PET analysis was conducted to assess the predictive value of the metabolic response to BR compared with the response by International Working Group (IWG) criteria. METHODS: Adult patients with relapsed or refractory MCL underwent (18)F-FDG PET at screening and after 6 cycles of BR therapy...
January 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27458003/brentuximab-vedotin-and-avd-followed-by-involved-site-radiotherapy-in-early-stage-unfavorable-risk-hodgkin-lymphoma
#16
Anita Kumar, Carla Casulo, Joachim Yahalom, Heiko Schöder, Paul M Barr, Philip Caron, April Chiu, Louis S Constine, Pamela Drullinsky, Jonathan W Friedberg, John F Gerecitano, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Alexandra G Jacob, Matthew J Matasar, Gianna N McArthur, Susan J McCall, Alison J Moskowitz, Ariela Noy, Maria L Palomba, Carol S Portlock, David J Straus, Nicholas VanderEls, Stephanie L Verwys, Joanna Yang, Anas Younes, Andrew D Zelenetz, Zhigang Zhang, Craig H Moskowitz
This multicenter pilot study assessed the safety and efficacy of brentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT). Patients with newly diagnosed, early stage classical Hodgkin lymphoma (HL) with unfavorable-risk features were treated with 4 cycles of BV and AVD. Patients who achieved a negative positron emission tomography (PET) scan (Deauville score of 1-3) received 30 Gy ISRT. Thirty patients received treatment and were assessable for toxicity...
September 15, 2016: Blood
https://www.readbyqxmd.com/read/27339738/fdg-pet-is-prognostic-and-predictive-for-progression-free-survival-in-relapsed-follicular-lymphoma-exploratory-analysis-of-the-gauss-study
#17
Lale Kostakoglu, Andre Goy, Giovanni Martinelli, Dolores Caballero, Michael Crump, Gianluca Gaidano, Tara Baetz, Rena Buckstein, Gregg Fine, Guenter Fingerle-Rowson, Claude Berge, Deniz Sahin, Oliver Press, Laurie Sehn
An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response. The proportion of patients with a PFS event (progression or death) was higher in those who were PET-positive after IT (assessed using Deauville five-point scale criteria; 35/52, 67%) than PET-negative (5/20, 25%); the hazard ratio for progression or death was 0...
June 24, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27246952/interim-fdg-pet-ct-in-hodgkin-lymphoma-the-prognostic-role-of-the-ratio-between-target-lesion-and-liver-suvmax-rpet
#18
Salvatore Annunziata, Annarosa Cuccaro, Maria Lucia Calcagni, Stefan Hohaus, Alessandro Giordano, Vittoria Rufini
OBJECTIVE: To evaluate the prognostic role of the ratio between target lesion and liver SUVmax (rPET) in patients with Hodgkin lymphoma (HL) undergoing interim FDG-PET/CT and to compare rPET with the 5-point Deauville Score (5p-DS). METHODS: Sixty-eight patients with HL undergoing interim FDG-PET/CT after first courses of chemotherapy were evaluated. The receiver operating characteristic (ROC) approach was applied to identify the optimal cutpoint of rPET with respect to progression free survival (PFS)...
October 2016: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/27154522/diagnostic-accuracy-of-fdg-pet-ct-for-clinical-evaluation-at-the-end-of-treatment-of-hl-and-nhl-a-comparison-of-the-deauville-criteria-dc-and-the-international-harmonization-project-criteria-ihpc
#19
MULTICENTER STUDY
Federico Fallanca, Pierpaolo Alongi, Elena Incerti, Luigi Gianolli, Maria Picchio, Irfan Kayani, Jamshed Bomanji
PURPOSE: To evaluate the accuracy and prognostic value of FDG PET/CT for response assessment after treatment in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) when using the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). METHODS: This retrospective study included 101 patients (35 HL, 66 NHL) who underwent early restaging FDG PET/CT after treatment. Scans were evaluated using the IHPC and DC. Two thresholds of positivity for the DC were used: a score of at least 3 (DC3, i...
September 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27130796/prognostic-role-of-pre-radiation-therapy-18-f-fluorodeoxyglucose-positron-emission-tomography-for-primary-mediastinal-b-cell-lymphomas-treated-with-r-chop-or-r-chop-like-chemotherapy-plus-radiation
#20
Andrea Riccardo Filippi, Cristina Piva, Mario Levis, Annalisa Chiappella, Daniele Caracciolo, Marilena Bellò, Gianni Bisi, Umberto Vitolo, Umberto Ricardi
PURPOSE: To validate, in a monoinstitutional cohort with extended follow-up, that post-rituximab chemotherapy (R-CT) (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) is a prognostic factor allowing discrimination of primary mediastinal B-cell lymphoma (PMBCL) patients at higher risk for progression after radiation therapy. METHODS AND MATERIALS: We analyzed 51 patients, and (18)FDG-PET scans were re-examined evaluating both the Deauville 5-point scale (D5PS) score and the standardized uptake value (SUV) of residual activity, if present...
July 15, 2016: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
91274
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"